Bayer
Bayer’s cardiovascular drug races to target in trial
February 9, 2017Research and Development, Sales and Marketing Bayer, Janssen, Xarelto
Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …
Five most talked about mergers and acquisitions of 2016
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma
2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …
Looking back at the biggest deal of 2016: Bayer-Monsanto
December 2, 2016Medical Communications Bayer, acquisition, big deal, monsanto, pharma deal 2016
The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September …
Roche, Bayer and more speak out against German pricing cap plans
November 14, 2016Sales and Marketing Bayer, Germany, Roche
A number of major drug manufacturers have spoken out against German government plans to cap prescription drug pricing in the …
Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal
October 14, 2016Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD
Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …
Sanofi lowers Q3 sales figures from 2015
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results
Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …
Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin
The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
NICE approves Bayer’s Eylea for NHS use
September 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE
Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …
Bayer CEO defends $66 billion Monsanto acquisition
September 20, 2016Manufacturing and Production, Sales and Marketing Bayer, Werner Baumann, monsanto
Bayer AG’s chief executive Werner Baumann has spoken in defence of the company’s move last week to acquire US agricultural …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
Bayer acquires Monsanto in largest-ever deal by a German company
September 14, 2016Business Services, Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto
Bayer and Monsanto have signed a definitive merger agreement under which the German drugmaker will acquire the US agricultural group …
Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition
September 12, 2016Business Services, Manufacturing and Production, Sales and Marketing Bayer, acquisition, monsanto
In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm …
Bayer takes another shot at Monsanto acquisition
September 6, 2016Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto
Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort …
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
